Federal: concentrated 7-OH
DEA published a 14 October 2026 notice of intent (91 FR 65370, document 2026-20943) to temporarily place 7-hydroxymitragynine and mitragynine pseudoindoxyl (MGPI) in Schedule I when above a specified threshold: greater than 1 mg/g (solids) or 1 mg/mL (liquids), or when the mitragynine-to-(7-OH and/or MGPI) mass ratio is less than 100. The July 2026 notice of intent on 7-OH was withdrawn. The notice states that neither HHS nor DEA has found below-threshold products “safe to use.” Primary sources: GovInfo PDF · Federal Register.
Federal: MGPI, MGM-15, MGM-16
Mitragynine pseudoindoxyl, MGM-15, and MGM-16 have been in Schedule I under a temporary order since 26 August 2026 (a separate FR action). On 14 October 2026 DEA also published companion notice 2026-20942 regarding continued temporary Schedule I placement of MGM-15 and MGM-16. Primary sources: GovInfo PDF · DOJ (9 Oct 2026).
FDA position
FDA states concentrated or enhanced 7-OH products are not approved drugs, lawful dietary ingredients, or authorized food additives, and has recommended scheduling and taken enforcement/seizure actions. Public messaging distinguishes concentrated products from natural leaf while warning about MP and related analogues.
Selected state actions (snapshot)
| Jurisdiction | Verified development | Clinical relevance |
|---|---|---|
| California | CDPH: kratom- and 7-OH-containing foods/supplements/unapproved drugs illegal to manufacture or sell for consumption; active enforcement/seizures. Food/drug enforcement ≠ blanket Schedule I listing. | Retail access can contract before federal scheduling. |
| Connecticut | Guidance reports Schedule I placement of kratom and 7-OH (verify current schedule). | State criminal exposure may already differ from federal status. |
| Florida | Emergency Rule 2ER26-1 (effective as verified July 1, 2026) places specified 7-OH-related compounds into Schedule I under rule terms. | State exposure while federal temporary orders remain pending. |
| New York | S8925A passed both chambers (June 2026); not shown enacted on bill page at last check—retail threshold proposal. | Civil retail prohibition ≠ Schedule I. |
| Texas | Public-health advisory on kratom and concentrated 7-OH. | Supports screening and education; not itself scheduling. |
Public-health signal
America’s Poison Centers reported 593 7-OH exposure reports in 2025 and 901 in January–June 2026. Among 7-OH-only reports, 38.8% were classified serious, 63.8% treated at a healthcare facility, and 20.5% hospitalized. Surveillance is not incidence—but the direction of travel is clear.
Treatment-capacity concern
Pairing regulation with clinician alerts, naloxone, rapid buprenorphine/methadone access, and surveillance for fentanyl substitution is the public-health point of this resource. See treatment and evidence.